Showing 1231-1240 of 3024 results for "".
- MS in Harmony Provides Access to the Benefits and Enjoyment of Music Therapy for Everyone Affected by Multiple Sclerosishttps://practicalneurology.com/news/ms-in-harmony-provides-access-to-the-benefits-and-enjoyment-of-music-therapy-for-everyone-affected-by-multiple-sclerosis/2469507/A new online platform, MSinHarmony.com has been launched and provides an engaging and interactive way to explore music therapy for people living with multiple sclerosis (MS). The site includes information about the music therapy and the growing body of ev
- Immunosuppressant Prodrug Shows Potential as Acute Treatment for Individuals Experiencing Severe MS Relapseshttps://practicalneurology.com/news/immunosuppressant-prodrug-shows-potential-as-acute-treatment-for-individuals-experiencing-severe-ms-relapses/2483587/Cyclophosphamide, an immunosuppressant prodrug, may provide meaningful benefit for people with multiple sclerosis (MS) who are experiencing severe relapses unresponsive to standard treatments such as corticosteroids or plasma exchange, according to new data from a clinic-based cohort study presen
- More than 50% of Patients with MS Discontinue Infusion Therapy Owing in Part to Travel Burdenhttps://practicalneurology.com/news/more-than-50-of-patients-with-ms-discontinue-infusion-therapy-owing-to-travel-burden/2475045/Study results presented at the 2025 Annual Meeting of The Consortium of Multiple Sclerosis Centers (cMSc) demonstrated low medication adherence and persistence rates among Medicare beneficiaries with multiple sclerosis (MS) treated with infusion-based disease modifying therapies (DMTs). Most high
- 6-Year Data Reported for Kesimpta Treatment of Individuals with Early, Non-Highly Active MShttps://practicalneurology.com/news/6-year-data-reported-for-kesimpta-treatment-of-individuals-with-early-non-highly-active-ms/2474006/Six-year open-label extension (OLE) results from the ALITHIOS clinical trial (NCT03650114) demonstrated that treatment with Kesimpta (ofatumumab; Novartis, East Hanover, NJ) was safe and effective for individuals with early multiple sclerosis (MS) and non-highly active disease taking continuous t
- High-Dose Vitamin D Monotherapy Reduced Disease Activity in CIS and Early Relapsing-Remitting MShttps://practicalneurology.com/news/high-dose-vitamin-d-monotherapy-reduced-disease-activity-in-cis-and-early-relapsing-remitting-ms/2473817/High-dose vitamin D (cholecalciferol) monotherapy significantly reduced disease activity in patients with clinically isolated syndrome (CIS) and early relapsing-remitting multiple sclerosis (RRMS) according to results of the D-Lay MS clinical trial (NCT01817166) published in JAMA. Conduc
- Research Presented at ANA 2024 Reveals Association Between Paramagnetic Rim Lesions and Disability/Disease Progression in People with MShttps://practicalneurology.com/news/research-presented-at-ana-2024-reveals-association-between-paramagnetic-rim-lesions-and-disabilitydisease-progression-in-people-with-ms/2470577/For people with multiple sclerosis (MS), a higher number of persisting paramagnetic rim lesions (PRLs) was associated with increased odds of progression independent of relapse activity (PIRA) and confirmed disability progression (CDP), according to data presented at the 2024 annual meeting of the
- Access and Cost of Neurologic Health Care May Provide a Link Between MS and Latitudehttps://practicalneurology.com/news/access-and-cost-of-neurologic-health-care-may-provide-a-link-between-ms-and-latitude/2470007/According to new research published in Neurology, the correlation between lower incidence of multiple sclerosis (MS) diagnosis and distance from the equator may be due to issues of access to care rather than biologic mechanisms of disease. The study results suggest undere
- FDA Approves Ofatumumab—First and Only Self-administered B-cell Therapy for Relapsing MShttps://practicalneurology.com/news/fda-approves-ofatumumab-first-and-only-self-administered-b-cell-therapy-for-relapsing-ms/2469358/The Food and Drug Administration (FDA) has approved ofatumumab (Kesimpta; Novartis) as an subcutaneous autoinjection for treatment of relapsing forms of multiple sclerosis (RS), including clinically isolated syndrome (CIS), relapsing-remitting disease (RRMS), and active secondary progressive MS (
- Combination Therapy Best for MS Fatiguehttps://practicalneurology.com/news/combination-therapy-best-for-ms-fatigue/2470125/Research results presented at the Americas Committee for Treatment & Research in Multiple Sclerosis
- BTK Inhibitor Compared With Ocrelizumab for Primary Progressive MShttps://practicalneurology.com/news/btk-inhibitor-compared-with-ocrelizumab-for-primary-progressive-ms/2485636/Study results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2026 demonstrated that fenebrutinib (Roche, Basel, Switzerland), an investigational oral Bruton tyrosine kinase (BTK) inhibitor, achieved noninferior efficacy compared with Ocrevus (